retatrutide type 2 diabetes phase 2 results 2024 2025 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ retatrutide phase 2 trial type

Meanwhile, pharmaceutical giants Novo Nordisk and Eli Lilly have gone on the offensive, filing dozens of lawsuits in multiple states against medical spas, weight-loss clinics and pharmacies

The program is designed for individuals with a BMI of 21 or higher, representing the vast majority of US adults

They used a mouse model of diet-induced obesity and combined metabolomic analyses in BAT and other tissues with stable-isotope tracer studies to answer this question

- 3 mg (3000 mcg)**: The highest dose available, providing maximum benefits for appetite suppression and weight loss

Health management decisions should occur with physician guidance